FIP1L1-PDGFRA-Negative HES: Removing Steroid, Not Just Adding a Second Drug
A single patient, whose disease is controlled but whose treatment has started costing him real ground. The disagreement isn't whether to add mepolizumab — it's whether it actually replaces his steroid burden or just sits alongside it.
Oscar D. lost his wife to a sudden cardiac event four months ago after thirty-one years of marriage, and has kept working through it largely because the alternative, sitting in an empty house, felt worse — he has landscaped properties across three counties for thirty years, work that keeps him outdoors in soil and standing water most of the growing season. His hypereosinophilic syndrome was diagnosed a year ago after a persistently elevated eosinophil count above 2,000 cells per microliter on two occasions eight weeks apart triggered an evaluation that ultimately found early eosinophilic myocardial involvement on cardiac MRI — patchy subendocardial late gadolinium enhancement without overt fibrosis yet — and confirmed his disease is FIP1L1-PDGFRA-negative — ruling out the one subtype that responds reliably to low-dose imatinib. Stool studies and a travel history were both negative for a parasitic driver, and his tryptase level didn't suggest an underlying mast cell process.
He has been maintained on prednisone since diagnosis, and it has worked — his eosinophil count and cardiac findings have both stabilized — but a year of chronic steroid exposure has cost him real, measurable ground: new-onset hyperglycemia requiring metformin, twenty pounds of weight gain, and a flattened mood his primary care doctor first attributed to grief alone before connecting it to his steroid dose. Mepolizumab, an anti-IL-5 monoclonal antibody, targets the eosinophil-driving cytokine directly rather than suppressing his immune system broadly the way prednisone does, and both trials behind it enrolled his exact subtype. Roufosse and colleagues, in the 2020 phase III trial, restricted enrollment to FIP1L1-PDGFRA-negative HES and found twenty-eight percent of mepolizumab-treated patients flaring against fifty-six percent on placebo. The steroid question was answered earlier, by Rothenberg and colleagues in 2008: in FIP1L1-PDGFRA-negative patients maintained on prednisone, eighty-four percent randomized to mepolizumab got down to ten milligrams daily or less for eight consecutive weeks, against forty-three percent on placebo. That second endpoint is the one describing Oscar — it was designed around the exact problem his hyperglycemia and twenty pounds represent.
Removing steroid, not just adding a second drug
His steroid toxicity has become its own real problem — new diabetes, significant weight gain, and a mood change his own doctor initially attributed entirely to grief. I'd start mepolizumab now specifically because it was studied in FIP1L1-PDGFRA-negative HES, his exact subtype, and demonstrated real steroid-sparing benefit alongside flare reduction.
Given how recently he lost his wife, disentangling his mood change from grief versus steroid effect is genuinely difficult — but that difficulty is itself an argument for removing one contributing variable rather than leaving it in place while we wait to see if the mood symptoms resolve on their own.
I agree the steroid toxicity is real and worth addressing directly, and I'm not arguing against mepolizumab in principle. But its response in HES generally, not just his FIP1L1-PDGFRA-negative subtype specifically, isn't universal, and I'd want a defined steroid-taper plan built in from the start rather than adding mepolizumab on top of his current prednisone dose indefinitely.
If we add a new drug without an explicit tapering target, there's a real risk he ends up on both indefinitely rather than mepolizumab actually replacing the steroid burden it's meant to reduce.
Agreed: start mepolizumab with an explicit, scheduled prednisone taper built into the plan from the outset, rather than adding it on top of his current steroid dose.
Not agreed: how much of his mood change to attribute to steroid tapering versus continued grief as the prednisone comes down — both voices agreed his primary care doctor should be looped in directly to track this rather than either specialist guessing at the split.